Cargando…
Alterations in Homologous Recombination-Related Genes and Distinct Platinum Response in Metastatic Triple-Negative Breast Cancers: A Subgroup Analysis of the ProfiLER-01 Trial
Background: a specific subset of metastatic triple-negative breast cancers (mTNBC) is characterized by homologous recombination deficiency (HRD), leading to enhanced sensitivity to platinum-based chemotherapy. Apart from mutations in BRCA1/2 genes, the evaluation of other HRD-related alterations has...
Autores principales: | Bonnet, Elise, Haddad, Véronique, Quesada, Stanislas, Baffert, Kim-Arthur, Lardy-Cléaud, Audrey, Treilleux, Isabelle, Pissaloux, Daniel, Attignon, Valéry, Wang, Qing, Buisson, Adrien, Heudel, Pierre-Etienne, Bachelot, Thomas, Dufresne, Armelle, Eberst, Lauriane, Toussaint, Philippe, Bonadona, Valérie, Lasset, Christine, Viari, Alain, Sohier, Emilie, Paindavoine, Sandrine, Combaret, Valérie, Pérol, David, Ray-Coquard, Isabelle, Blay, Jean-Yves, Trédan, Olivier |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604780/ https://www.ncbi.nlm.nih.gov/pubmed/36294734 http://dx.doi.org/10.3390/jpm12101595 |
Ejemplares similares
-
Therapeutic relevance of molecular screening program in patients with metastatic sarcoma: Analysis from the ProfiLER 01 trial
por: Arnaud-Coffin, Patrick, et al.
Publicado: (2020) -
Precision medicine for patients with gastro-oesophageal cancer: A subset analysis of the ProfiLER program
por: Cassier, Philippe A., et al.
Publicado: (2021) -
TP53 Mutation as a Prognostic and Predictive Marker in Sarcoma: Pooled Analysis of MOSCATO and ProfiLER Precision Medicine Trials
por: Nassif, Elise F., et al.
Publicado: (2021) -
Pembrolizumab in Lymphopenic Metastatic Breast Cancer Patients Treated with Metronomic Cyclophosphamide: A Clinical and Translational Prospective Study
por: Mery, Benoîte, et al.
Publicado: (2023) -
Profi-user-guide
por: Stroede, J
Publicado: (2022)